Glaucoma :: Patients at Risk for Glaucoma Will Benefit From Risk Assessment Tool
A combined analysis of two landmark clinical glaucoma trials — the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS) — confirms the benefit of a five-year risk assessment model to help ophthalmologists better predict which patients have an increased risk of developing glaucoma. Glaucoma is the second leading cause of blindness in the world, affecting approximately 70 million people, and can lead to blindness if left untreated. These new data were presented this week at the annual American Academy of Ophthalmology meeting.